Posted by Michael Wonder on 28 Feb 2023
Darolutamide receives approval for additional prostate cancer indication in Japan
27 February 2023 - New approval is based on data from the pivotal Phase 3 ARASENS trial.
The Ministry of Health, Labor and Welfare in Japan has approved the oral androgen receptor inhibitor darolutamide in combination with androgen deprivation therapy and docetaxel in the indication of metastatic prostate cancer.
